← ANALYST RATINGS · TIPRANKS
Sionna Therapeutics, Inc. (SION): analyst forecast and price target
Analyst consensus
Hold0 Buy6 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $20.25, the highest $63.00, the lowest $5.00. The average is +420.6% from the last price of $3.89.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Sell | −10.0% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Sell | −10.0% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | −10.0% | Upgrade | 17.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | +2.8% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | +2.8% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.50 → $4.00−11.1% | Hold | +2.8% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% | LifeSci Capital | $6.00 | Hold | +54.2% | Reiterated | 19.09.26on TipRanks 10:30 | −0.9%next day +0.3% · 5 days −13.6% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | — | Hold | — | Reiterated | 15.09.26on TipRanks Sep 16 07:10 | −16.2%next day +2.8% · 5 days −14.9% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $5.00 → $6.00+20.0% | Hold | +54.2% | Reiterated | 15.09.26on TipRanks 08:08 | −16.2%next day +2.8% · 5 days −14.9% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $7.00 | Hold | +79.9% | Reiterated | 15.09.26on TipRanks 06:31 | −16.2%next day +2.8% · 5 days −14.9% | ↗ |
| Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% | Freedom Capital Markets | $38.00 → $5.00−86.8% | Hold | +28.5% | Reiterated | 11.08.26on TipRanks 10:21 | +13.7%next day +22.3% · 5 days +16.9% | ↗ |
| Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% | BTIG | — | Hold | — | Downgrade | 10.08.26on TipRanks 15:25 | −91.2%next day +13.7% · 5 days +31.4% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | — | Hold | — | Downgrade | 10.08.26on TipRanks 12:00 | −91.2%next day +13.7% · 5 days +31.4% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | — | Hold | — | Downgrade | 10.08.26on TipRanks 11:31 | −91.2%next day +13.7% · 5 days +31.4% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $23.00 → $5.00−78.3% | Hold | +28.5% | Upgrade | 10.08.26on TipRanks 11:13 | −91.2%next day +13.7% · 5 days +31.4% | ↗ |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $63.00 | Hold | +1,519.5% | Downgrade | 10.08.26on TipRanks 06:50 | −91.2%next day +13.7% · 5 days +31.4% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | — | Buy | — | Reiterated | 17.07.26on TipRanks Jul 24 05:09 | +10.1%next day −7.4% · 5 days −6.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Sionna Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.33 at a price of $5.26 (+191.5%); now: $15.33 at $3.89 (+294.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 11 | 10 | 12 | 5 | 3 | 1 |
| Hold | 0 | 0 | 0 | 6 | 9 | 9 |
| Sell | 2 | 1 | 1 | 1 | 1 | 1 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.64 (from $-0.84 to $-0.36). Last quarter: $-0.66.
Best top-analyst consensus in the sector · General
About Sionna Therapeutics, Inc.
- CEO: Michael Cloonan
- Employees: 59
- 21 Hickory Drive Suite 500, Waltham, MA, 02451, US
- www.sionnatx.com
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 102 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗